Sanofi has finalized its acquisition of Vicebio Ltd, a company specializing in vaccine development. The deal adds an early-stage combination vaccine candidate targeting respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) to Sanofi’s portfolio. Both viruses are known to cause respiratory infections.
The acquisition also gives Sanofi access to Vicebio’s ‘Molecular Clamp’ technology, which is expected to enhance the company’s capabilities in designing and developing vaccines. By adding this non-mRNA vaccine candidate, Sanofi aims to broaden its pipeline and provide more options for physicians and patients dealing with RSV and HMPV.
According to the company, “This acquisition brings an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV), both respiratory viruses, and expands the capabilities in vaccine design and development with Vicebio’s ‘Molecular Clamp’ technology.”
Sanofi stated that the acquired vaccine complements its existing work in respiratory vaccines. “It enables Sanofi to offer increased physician and patient choice in RSV and HMPV by adding a non-mRNA vaccine to its pipeline,” the company said.
Sanofi describes itself as an R&D driven, AI-powered biopharma company focused on improving lives through medicines and vaccines. The firm says it is committed to delivering growth while addressing healthcare challenges worldwide.
